Get the Stockscreener App
98.34
0.41%
0.76
Inhibrx Biosciences Inc stock is traded at $98.34, with a volume of 302.21K.
It is up +0.41% in the last 24 hours and up +12.61% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$97.58
Open:
$97.48
24h Volume:
302.21K
Relative Volume:
0.70
Market Cap:
$1.43B
Revenue:
$1.30M
Net Income/Loss:
$-140.06M
P/E Ratio:
-10.87
EPS:
-9.0441
Net Cash Flow:
$-129.83M
1W Performance:
+2.60%
1M Performance:
+12.61%
6M Performance:
+28.76%
1Y Performance:
+500.02%
1-Day Range:
$95.00
$99.91
1-Week Range:
$91.37
$103.79
52-Week Range:
$15.82
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
97.80 | 1.39B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
528.70 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.99 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.39 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.73 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Index - marketscreener.com
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In? - Sahm
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
INBX News | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences urges continued research to address unmet needs in rare cancer treatment - Traders Union
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
INBX Forecast — Price Target — Prediction for 2027 - TradingView
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart - Sahm
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
(INBX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart - Sahm
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences Inc (INBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibrx Biosciences Inc (INBX) Institutional Confidence - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibrx Biosciences Inc (INBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Pa - GuruFocus
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy - TipRanks
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy - Stock Titan
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com - Investing.com Australia
FDA accepts Inhibrx Biosciences filing for ozekibart in metastatic chondrosarcoma - Traders Union
Inhibrx Biosciences stock gains after FDA accepts drug filing - Investing.com
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com South Africa
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients With Conventional Chondrosarcoma - Moomoo
Number of shareholders of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
(INBX) Risk Channels and Responsive Allocation - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Stock Gains on Operational UpdatesRetail Earnings Report - newsline.com
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike - Stock Titan
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options - Stock Titan
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22 - Stock Titan
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting - TipRanks
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO - Stock Titan
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Stifel reiterates Inhibrx Biosciences stock rating on durability data By Investing.com - Investing.com Canada
Inhibrx Biosciences targets research advances at ASCO26 to accelerate new cancer treatments - Traders Union
INBX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue R&D FocusEPS Growth Report - newsline.com
Inhibrx Biosciences (INBX) Slips 2% as Stock Tests Key Support Amid Biotech VolatilityVolatility Breakout Picks - The Legal Advocate
(INBX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Inhibrx Biosciences (INBX) Edges Higher as Stock Holds Above SupportRVOL Spike - The Legal Advocate
INBXInhibrx Biosciences Inc Stock Price and Quote - Finviz
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):